- The supply would be carried out after clinical studies are conducted in the country and the Vietnamese authorities grant their approval.

- The agreement is framed around HIPRA’s commitment to establishing agreements that make HIPRA’s COVID-19 vaccine accessible worldwide and to ending the pandemic.

The HIPRA pharmaceutical company has signed an agreement to supply 50 million doses of the HIPRA COVID-19 vaccine in Vietnam, aimed at helping fight against the pandemic. The supply would be carried out after local clinical studies are conducted in the country and the Vietnamese authorities grant their approval.

With this cooperation agreement, Vietnam could offer its population a solution against the COVID-19 pandemic and increase its vaccination rate.

The HIPRA vaccine has arouse Vietnam’s interest because it uses a recombinant protein-based platform designed to optimise safety and induce a potent immune response that neutralises COVID-19. The adjuvant used is like the one that has been used for more than 20 years in other human vaccines, such as the influenza vaccine, which is proven to be safe. One of the benefits offered is that it is stored at 2º–8ºC, making its distribution and logistics easier. Vietnam has seen HIPRA as a reliable company because of its rigour in meeting agreed-upon deadlines and its ability to ensure supply.

The cooperation agreement was signed this Saturday in Helsinki, where part of HIPRA’s Management travelled to meet several representatives from the Vietnamese government, among other parties.

HIPRA is continuing its ongoing conversations with global organisations and governments through embassies to spread awareness about the benefits of HIPRA’s vaccine. HIPRA’s commitment is to establish agreements that make the HIPRA COVID-19 vaccine accessible worldwide to help end the pandemic.